President Trump is pushing drugmakers to maneuver manufacturing again to the US. He is upping the ante with tariffs to encourage the shift. However would tariffs on imported medicine be sufficient?
SCOTT SIMON, HOST:
President Trump is pushing pharmaceutical firms to maneuver manufacturing again to the US. And this week, he upped the ante by saying he would impose tariffs on drugmakers as quickly as August 1. These tariffs would begin low to offer them a 12 months or so to construct factories right here after which quickly improve. NPR prescribed drugs correspondent Sydney Lupkin joins us. Sydney, thanks a lot for being with us.
SYDNEY LUPKIN, BYLINE: Thanks for having me.
SIMON: Assist us pay money for the issue. What number of of our medicines are literally made outdoors the U.S.?
LUPKIN: Loads of them – most of them, truly. Lots of the key substances are made in China and most generics are made in India. That is in response to economist Geoffrey Joyce, the director of well being coverage on the USC Schaeffer Heart.
GEOFFREY JOYCE: Some remaining formulation could also be finished within the U.S., however broadly talking, we’re very depending on overseas suppliers. It is much less intensive for branded or on-patent medicine, however nonetheless, we’re very dependent as effectively on abroad manufacturing.
LUPKIN: The USA was actually made conscious of how susceptible its drug provide was when COVID hit. Instantly, Chinese language drug factories shut down. India restricted drug exports. So having extra medicine produced within the U.S., particularly important medicines, is broadly thought-about a very good coverage.
SIMON: How was it that manufacturing moved outdoors the U.S. anyway?
LUPKIN: Yeah. There are tax incentives for manufacturing abroad. So by manufacturing name-brand medicine in Eire, for instance, firms can report income there and pay a really low company tax price. For generics, as a result of they compete totally on worth, firms manufacture in locations with decrease wages, like India and China. The tariffs are an effort to shift manufacturing again to the U.S. soil by principally punishing firms for overseas manufacturing.
SIMON: Will that work?
LUPKIN: It is difficult. Joyce says he thinks it might take much more incentives to persuade firms to do it – tax breaks, subsidies, issues like that. I additionally spoke to Chris Middendorf, who spent years on the Meals and Drug Administration inspecting factories in India and China, and he is now on the regulation agency Hogan Lovells. And he says it is a massive elevate to maneuver factories for even only one drug.
CHRIS MIDDENDORF: It is not nearly, like, placing the tools in and beginning to manufacture it. It is like, it’s a must to qualify the constructing. It’s important to qualify all of your tools in there. Like, it’s a must to set up all of your procedures for that website. It is much more than simply constructing a constructing.
LUPKIN: Firms have to show they’ll accurately make the drug at a brand new manufacturing facility. As a result of if they cannot, the implications for sufferers could possibly be dire.
SIMON: Yeah, after all. The prescribed drugs could possibly be dangerous.
LUPKIN: Yeah. All that mentioned, some firms have already introduced they’re increasing within the U.S. Eli Lilly is beefing up its home manufacturing, together with at websites in Indiana and North Carolina. And in February, it mentioned that it might be spending billions extra {dollars} so as to add 4 new factories. However Lilly says it might take so long as 5 years for these factories to come back on-line. So that is the life like timeline.
SIMON: Sydney, might firms simply principally ignore the tariffs or soak up them and go away manufacturing abroad?
LUPKIN: Sure, completely. That is an choice. The pharmaceutical tariff does not exist in a vacuum. There are a bunch of different tariffs, too. If an organization decides to construct a facility within the U.S., it would nonetheless get hit with tariffs importing tools. And for generic producers, whose income are razor-thin, a tariff won’t be a lot of an incentive to maneuver manufacturing. They could move alongside the tariff prices to customers or pull out of the market altogether.
SIMON: What would the implications of that be for sufferers?
LUPKIN: Each Joyce and Middendorf count on medicine would get dearer for customers or tariffs might end in entry points if firms cease promoting foreign-made merchandise right here, particularly generics. The large questions now are, will the drug tariffs actually be the 200% President Trump is threatening or one thing decrease, and can they stick?
SIMON: NPR pharmaceutical correspondent Sydney Lupkin. Thanks a lot.
LUPKIN: You guess.
Copyright © 2025 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional info.
Accuracy and availability of NPR transcripts could differ. Transcript textual content could also be revised to appropriate errors or match updates to audio. Audio on npr.org could also be edited after its unique broadcast or publication. The authoritative report of NPR’s programming is the audio report.
